Johnson & Johnson Rated ‘Moderate Buy’ by Analysts
December 29, 2022
Trending News 🌥️
Johnson & Johnson ($NYSE:JNJ) is one of the world’s largest and most renowned healthcare companies. Its stock has grown steadily over the years and is traded on the New York Stock Exchange (NYSE). Recently, analysts have given Johnson & Johnson a “Moderate Buy” rating. This means that analysts believe that the company is a good long-term investment, but may not be as attractive in the short-term. This is largely due to the fact that the company has had a relatively slow growth rate over the past few years. Analysts are encouraged by Johnson & Johnson’s strong financials and overall stability. The company has generated steady cash flow over the years, with no major debt issues to speak of.
Analysts also point to Johnson & Johnson’s strong dividend yield of over 3%. This is a great sign for investors who are looking for income in addition to capital appreciation. Furthermore, the company has a history of increasing its dividend payments over time, providing investors with a steady stream of income. The company’s strong financials and consistent performance have made it a safe and attractive investment for many investors. With an average rating of “Moderate Buy,” analysts are recommending that investors consider investing in Johnson & Johnson for long-term growth potential.
Stock Price
The stock opened at $178.1 and closed at $177.4, and so far media exposure of the company has been mostly positive. The pharmaceutical giant has had a long history of being a leader in the healthcare industry. J&J has a wide range of products and services, from consumer goods to medical devices, making it a major player in the healthcare sector. In recent years, J&J has been investing heavily in research and development, as well as expanding its global presence, which has helped to drive its growth and profitability. The company also has an extensive portfolio of products and services, which has enabled it to remain competitive in the marketplace. Analysts believe that J&J’s strong financials and good track record make it a good investment. They say that the company’s brand recognition and reputation in the healthcare sector make it a solid choice for investors looking to diversify their portfolios.
Additionally, J&J’s stock has outperformed the market over the past few years, making it an attractive option for investors seeking potential returns. Overall, J&J looks to be a safe and reliable stock for investors. With its strong financials and reputation, analysts rate it as a ‘Moderate Buy’. Investors should consider adding J&J to their portfolios if they are looking for a diversified healthcare option that offers potential returns. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for JNJ. More…
| Total Revenues | Net Income | Net Margin |
| 96.04k | 19.16k | 19.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for JNJ. More…
| Operations | Investing | Financing |
| 23.42k | -6.19k | -18.02k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for JNJ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 179.23k | 108.96k | 26.88 |
Key Ratios Snapshot
Some of the financial key ratios for JNJ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.5% | 4.6% | 24.8% |
| FCF Margin | ROE | ROA |
| 24.3% | 21.2% | 8.3% |
VI Analysis
Johnson & Johnson is an example of a company that has achieved moderate revenue or earnings growth, and is classified as a ‘rhino’ according to the VI Star Chart. Such companies may be of interest to investors looking for a steady stream of income and long-term potential. Johnson & Johnson is strong in dividend and profitability, and medium in asset and growth. It also has a high health score of 9/10 when it comes to its cashflows and debt, indicating that it is financially capable of paying off debt and funding future operations. Generally speaking, companies like Johnson & Johnson tend to be less risky investments than those with higher growth potential. They may provide investors with a lower return in the short term, but they can also offer stability and a reliable source of income over the long haul. Additionally, they often have strong fundamentals and are well-positioned to weather any short-term market volatility. Ultimately, investors must decide whether or not to invest in Johnson & Johnson based on their own risk tolerance and investment goals. More…
VI Peers
The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.
Summary
Johnson & Johnson has recently been rated as a ‘Moderate Buy’ by analysts, with favorable media coverage. Investors are advised to consider the company’s strong financial performance, low debt levels and good dividend yield when making their decision. The company has a large product portfolio, which includes medical devices, pharmaceuticals, consumer products, and animal health products. Investing in Johnson & Johnson can offer investors an attractive mix of potential growth and a steady dividend stream.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
